Narinder Singh Shargill, PhD, is Vice President of Global Medical Affairs at Pulmonx, a global leader in interventional pulmonology, planning tools, and treatments for obstructive lung disease. Narinder has 30+ years of experience taking medical devices through clinical development, regulatory approvals, and post-approval support through Medical Affairs’ activities, including 20+ years in interventional pulmonology. He led execution of key clinical trials leading to FDA approval of the Zephyr Valves in the US. Before Pulmonx, Narinder was Vice President, Clinical Strategy and Medical Affairs–Pulmonary at Boston Scientific and played a key global role supporting the Alair® Bronchial Thermoplasty System. Previously, he was Vice President, Clinical Affairs at Asthmatx, where his efforts led to the first therapeutic device approval in interventional pulmonology. Narinder also worked with Baxter following its acquisition of Fusion Medical Technologies, Nycomed Salutar, and Scios Inc. He holds a PhD in Nutrition/Biochemistry from the University of Southampton and completed post-doctoral training at the University of Southern California School of Medicine and School of Pharmacy.
Patients who were previously facing challenges like needing oxygen after just a few steps or struggling with breathlessness from simple movements are finding new possibilities for daily life.